Mark Wigglesworth

3.5k total citations
38 papers, 670 citations indexed

About

Mark Wigglesworth is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Biophysics. According to data from OpenAlex, Mark Wigglesworth has authored 38 papers receiving a total of 670 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 8 papers in Cellular and Molecular Neuroscience and 5 papers in Biophysics. Recurrent topics in Mark Wigglesworth's work include Receptor Mechanisms and Signaling (9 papers), Neuropeptides and Animal Physiology (6 papers) and CRISPR and Genetic Engineering (4 papers). Mark Wigglesworth is often cited by papers focused on Receptor Mechanisms and Signaling (9 papers), Neuropeptides and Animal Physiology (6 papers) and CRISPR and Genetic Engineering (4 papers). Mark Wigglesworth collaborates with scholars based in United Kingdom, United States and Sweden. Mark Wigglesworth's co-authors include Graham Ladds, Tom Ellis, David Öling, Niklas Larsson, David Bell, Hitoshi Yamauchi, Glen-Oliver F. Gowers, W. M. Shaw, Daniel J Donnelly and Elizabeth R. Quinn and has published in prestigious journals such as Cell, Biochemical and Biophysical Research Communications and Journal of Medicinal Chemistry.

In The Last Decade

Mark Wigglesworth

37 papers receiving 661 citations

Peers

Countries citing papers authored by Mark Wigglesworth

Since Specialization

Citations

This map shows the geographic impact of Mark Wigglesworth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Wigglesworth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Wigglesworth more than expected).

Fields of papers citing papers by Mark Wigglesworth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Wigglesworth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Wigglesworth. The network helps show where Mark Wigglesworth may publish in the future.

Co-authorship network of co-authors of Mark Wigglesworth

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Wigglesworth. A scholar is included among the top collaborators of Mark Wigglesworth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Wigglesworth. Mark Wigglesworth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	RT-PCR genotyping assays to identify SARS-CoV-2 variants in England in 2021: a design and retrospective evaluation study 2024 ·The Lancet Microbe ·(unknown), Will Sopwith, Matt Edmunds, Harper VanSteenhouse, Jelena D. Milosevic Feenstra, Peter Jacobs, (unknown), Anne Marie O’Connell, (unknown), Paula Blomquist, (unknown), Richard Elson, Roberto Vivancos, Eileen Gallagher, Mark Wigglesworth, Anna F. Dominiczak, Susan Hopkins, Iain Lake	5
2	High throughput diagnostics and dynamic risk assessment of SARS-CoV-2 variants of concern 2021 ·EBioMedicine ·Alfredo Maria Gravagnuolo, (unknown), (unknown), (unknown), Paul E. Klapper, Mark Wigglesworth	16
3	A Perspective on Synthetic Biology in Drug Discovery and Development—Current Impact and Future Opportunities 2021 ·SLAS DISCOVERY ·Florian David, A. M. Davis, Michael Gossing, Martin A. Hayes, Elvira Romero, (unknown), Mark Wigglesworth	22
4	CGRP, adrenomedullin and adrenomedullin 2 display endogenous GPCR agonist bias in primary human cardiovascular cells 2021 ·Communications Biology ·(unknown), N Mullooly, (unknown), Matthew Harris, Tessa de Vries, Antoinette MaassenVanDenBrink, David R. Poyner, Davide Gianni, Mark Wigglesworth, Graham Ladds	25
5	Engineering a Model Cell for Rational Tuning of GPCR Signaling 2019 ·Cell ·W. M. Shaw, Hitoshi Yamauchi, (unknown), Glen-Oliver F. Gowers, David Bell, David Öling, Niklas Larsson, Mark Wigglesworth, Graham Ladds, Tom Ellis	129
6	Large Scale Synthetic Site Saturation GPCR Libraries Reveal Novel Mutations That Alter Glucose Signaling 2018 ·ACS Synthetic Biology ·David Öling, (unknown), W. M. Shaw, Sonya Clark, Ross Kettleborough, Tom Ellis, Niklas Larsson, Mark Wigglesworth	4
7	Techniques to Enable 1536-Well Phenotypic Screening 2018 ·Methods in molecular biology ·(unknown), Helen Plant, Lisa McWilliams, Mark Wigglesworth	1
8	Enabling 1536-Well High-Throughput Cell-Based Screening through the Application of Novel Centrifugal Plate Washing 2017 ·SLAS DISCOVERY ·(unknown), Helen Plant, Lisa McWilliams, David C. Murray, (unknown), (unknown), Paul Harper, Anna Ramne, (unknown), (unknown), (unknown), (unknown), Mark Wigglesworth	14
9	High affinity binding of the peptide agonist TIP-39 to the parathyroid hormone 2 (PTH 2 ) receptor requires the hydroxyl group of Tyr-318 on transmembrane helix 5 2016 ·Biochemical Pharmacology ·(unknown), Juan Carlos Mobarec, Mark Wigglesworth, Christopher A. Reynolds, Daniel J Donnelly	9
10	Validation of Miniaturized One-Step Reverse Transcription qPCR Assays for High-Throughput Screening and Comparison to a Reporter Gene Methodology 2015 ·Assay and Drug Development Technologies ·Catherine Bardelle, Lisa McWilliams, (unknown), Mark Wigglesworth, (unknown)	3
11	A salt bridge between Arg-20 on parathyroid hormone (PTH) and Asp-137 on the PTH1 receptor is essential for full affinity 2014 ·Peptides ·(unknown), Mark Wigglesworth, Daniel J Donnelly	3
12	Screening β-Arrestin Recruitment for the Identification of Natural Ligands for Orphan G-Protein–Coupled Receptors 2013 ·SLAS DISCOVERY ·C. Southern, Jennifer M. Cook, (unknown), Debra L. Taylor, Catherine Kettleborough, Andy Merritt, Daniel L. Bassoni, William J. Raab, Elizabeth R. Quinn, Tom S. Wehrman, Anthony P. Davenport, Andrew J. Brown, Andrew R. Green, Mark Wigglesworth, Steve Rees	150
13	Management of chemical and biological samples for screening applications 2012 ·Wiley-VCH eBooks ·Mark Wigglesworth, Terry Wood	7
14	Towards the Discovery of New Hypnotic Agents: Synthesis and Preliminary Pharmacological Evaluation of a Novel Class of Dibenzo[a,d]cycloheptene Derivatives 2010 ·ChemMedChem ·(unknown), (unknown), (unknown), Stephen Brough, (unknown), (unknown), Massimo Gianotti, Carla Marchioro, (unknown), (unknown), Mark Wigglesworth, Maurizio Botta	1
15	Innovation Leading the Way: Application of Lean Manufacturing to Sample Management 2009 ·SLAS DISCOVERY ·Michael Allen, Mark Wigglesworth	9
16	Identification of a novel asthma susceptibility gene on chromosome 1qter and its functional evaluation 2008 ·Human Molecular Genetics ·John H. White, Mathias Chiano, Mark Wigglesworth, Robert S. Geske, J. Riley, Nicholas J. White, Sue Hall, Guohua Zhu, (unknown), Thomas F. Savage, W. J. Anderson, (unknown), Monika Ducceschi, (unknown), Jørgen Vestbo, (unknown)	50
17	Use of Cryopreserved Cells for Enabling Greater Flexibility in Compound Profiling 2008 ·SLAS DISCOVERY ·Mark Wigglesworth, (unknown), (unknown), (unknown), (unknown), Fiona C. McKay, E. Sally Ward, Stephen Brough, Marinos Stylianou, Frances Jewitt, (unknown), (unknown), (unknown), (unknown), Jing Ding, Alan Wise	15
18	Orphan Seven Transmembrane Receptor Screening 2007 ·PubMed ·Mark Wigglesworth, Lynne A. Wolfe, Alan Wise	6
19	Considering the case for an antidepressant drug trial involving temporary deception: a qualitative enquiry of potential participants 2007 ·BMC Health Services Research ·Christopher Dowrick, John Hughes, Julia Hiscock, Mark Wigglesworth, Thomas Walley	8
20	On the role of 5‐HT_1B/1D receptors in modulating transmission in a spinal reflex pathway in the decerebrated rabbit 1999 ·British Journal of Pharmacology ·(unknown), Mark Wigglesworth, (unknown), (unknown), R.W. Clarke	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact